Patients experienced an average weight loss of 20.4% at 24 months while using and the WeGoTogether patient support program.
The study included 8177 adults with overweight or obesity, with 93.0% having a BMI of 30.0 kg/m or higher.
Weight loss averaged 13.4% at 6 months, 17.6% at 12 months, 20.3% at 18 months, and 20.4% at 24 months.
Proportions of patients achieving at least 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively.
Similar weight loss results were observed in patients with a BMI of 30.0 kg/m or higher.
Simplified
INTRODUCTION: injection 2.4 mg (Wegovy; hereafter referred to as semaglutide) was approved by the US Food and Drug Administration in June 2021 for chronic weight management in adults with overweight or obesity. This study aimed to evaluate the real-world long-term effectiveness of semaglutide in combination with the WeGoTogether patient support program with a follow-up period of up to 24 months. ®
METHODS: This retrospective, noninterventional cohort study included adults with overweight or obesity (body mass index [BMI] ≥ 25.0 kg/m) who initiated semaglutide and enrolled in WeGoTogether during the study period (6/2021-4/2025). Semaglutide is administered as a once-weekly subcutaneous injection. Patients had ≥ 2 post-index weights, with ≥ 1 weight at 6, 12, 18, and/or 24 months (± 30 days) of follow-up. Self-reported, de-identified data from WeGoTogether were analyzed descriptively. Patient demographics were characterized, and changes in weight and BMI were compared from index to each follow-up time point. 2
RESULTS: Overall, 8177 patients met the eligibility criteria, including 7604 (93.0%) patients with a BMI ≥ 30.0 kg/m. At baseline, the mean age was 49.5 years, mean weight was 234.1 lb, and mean BMI was 38.4 kg/m; 83.6% of patients were female. Among patients with reported weight at the time points of interest, the mean (standard deviation) percent weight loss was - 13.4% (6.4) at 6 months (n = 6964), - 17.6% (10.2) at 12 months (n = 2050), - 20.3% (11.4) at 18 months (n = 491), and - 20.4% (11.3) at 24 months (n = 325). The proportions of patients achieving ≥ 20% weight loss were 13.1%, 43.3%, 52.5%, and 50.5% at 6, 12, 18, and 24 months, respectively. Similar results were observed for the subgroup with BMI ≥ 30.0 kg/m. 2 2 2
CONCLUSION: The study demonstrated substantial weight loss with semaglutide treatment, including over long-term 18- and 24-month follow-up periods, as reported in the . These data suggest patients can achieve clinically meaningful long-term (24 months) weight loss in real-world settings when treated with semaglutide and participating in the WeGoTogether patient support program.
Key numbers
-20.4%
Mean Percent Weight Loss
Percent weight loss at 24 months among patients with BMI ≥ 25.0 kg/m.
50.5%
Proportion Achieving ≥ 20% Weight Loss
Proportion of patients at 24 months.
8177
Total Patients in Study
Total number of patients who met eligibility criteria.
Full Text
We can’t show the full text here under this license.
Declarations. Conflict of Interest: Joshua C. Toliver, Victoria Divino, Carmen D. Ng, and Julia Wang are employees and shareholders of Novo Nordisk Inc. Ethical Approval: This study was performed in accordance with relevant guidelines and regulations, including the principles of the Helsinki Declaration of 1964 and its later amendments. This study used only secondary, de-identified data and did not involve the collection, use, or transmittal of individually identifiable data. WCG Institutional Review Board (Cary, NC, USA) granted a waiver exemption for this study from full institutional review board review. All patients enrolled in the WeGoTogether patient support program provided consent for their de-identified data to be used for research purposes.
